On Thursday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Parker-Hannifin Corporation (NYSE:PH), Skyworks Solutions Inc (NASDAQ:SWKS), Akorn, Inc (NASDAQ:AKRX), Biogen Inc (NASDAQ:BIIB)
Parker-Hannifin Corporation (NYSE:PH)’s shares dwindled -0.35%, and closed at $118.00. The stock volatility for the week is 1.49%, while for the month remained 1.71%. The company holds consensus target price of $130.00.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 7.25 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 9.70% and Annual EPS growth for the past 5 years is considered as 17.00%.
The mean recommendation of analysts for this stock is 2.30. (where 1=Buy, 5=Sale).
Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for various mobile, industrial, and aerospace markets worldwide. It operates through two segments, Diversified Industrial and Aerospace Systems. The Diversified Industrial segment provides pneumatic, fluidic, and electromechanical components and systems; filters, systems, and diagnostics solutions to monitor and remove contaminants from fuel, air, oil, water, and other liquids and gases; connectors, which control, transmit, and contain fluid; hydraulic components and systems for builders and users of industrial and mobile machinery and equipment; critical flow components for process instrumentation, healthcare, and ultra-high-purity applications, in addition to components for use in refrigeration and air conditioning systems, and in fluid control applications for processing, fuel dispensing, beverage dispensing, and mobile emissions; and static and dynamic sealing devices.
Skyworks Solutions Inc (NASDAQ:SWKS), declined -0.34%, and closed at $96.51. The stock has price to sale ratio of 7.11, however, price to book ratio is 6.72. With recent decline, the year-to-date (YTD) performance reflected a 32.95% incline below last year. During the past month the stocks gain 7.04%, bringing three-month performance to 32.95% and six-month performance to 81.72%. The mean recommendation of analysts for this stock is 1.80. (where 1=Buy, 5=Sale).
Skyworks Solutions, Inc., together with its subsidiaries, designs, develops, manufactures, and markets analog and mixed signal semiconductors worldwide. Its product portfolio comprises amplifiers, attenuators, battery chargers, circulators, DC/DC converters, demodulators, detectors, diodes, directional couplers, filters, front-end modules, hybrids, infrastructure radio frequency subsystems, isolators, LED drivers, mixers, modulators, optocouplers, optoisolators, phase shifters, phase locked loops/synthesizers/VCOs, power dividers/combiners, power administration devices, receivers, switches, technical ceramics, and voltage regulators.
Akorn, Inc (NASDAQ:AKRX), dipped -0.34%, and closed at $47.24. The company holds the market capitalization of $5.40B. For the last twelve months, the stock was able to keep return on equity at 11.10%, while return on assets at 2.60%, in response to its return on investment at 5.50%. Its 20-day moving average gained 0.10%, above 50-day moving average of 1.01%, above 200-day moving average of 19.87% from the latest market price of $47.24. The mean recommendation of analysts for this stock is 1.80.(where 1=Buy, 5=Sale).
Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, in addition to animal and over-the-counter (OTC) consumer health products in the United States and internationally. It operates through two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment markets generic and branded ophthalmics, injectables, oral liquids, otics, topical, inhalants, and nasal sprays. This segment’s generic products comprise Clobetasol Propionate, a corticosteroid, which is used to treat various skin conditions; Fluticasone Propionate, a corticosteroid used for nasal symptoms of allergic and non-allergic rhinitis conditions; Lidocaine/Prilocaine, a topical anesthetic; Progesterone, which is used to prevent endometrial hyperplasia; Vancomycin, an antibiotic used to treat bacterial infections; and other products.
Biogen Inc (NASDAQ:BIIB), dropped -0.33%, and closed at $412.44. The stock has the beta value of 97.09B, and its volatility for the week is 2.36%, while for the month it is 2.58%. The company has the market capitalization of $96.76B. The company holds the book value per share of 45.90, whereas cash per share is 7.87. Price to book ratio remained 8.99, while price to sale ratio is 9.97. Analysts mean recommendation for the stock is said to be 2.00 (where 1=Buy, 5=sale).
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company’s products that accomplished Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials comprise of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin’s lymphoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
